CN108949997A - A kind of lung cancer detection marker and diagnostic kit - Google Patents
A kind of lung cancer detection marker and diagnostic kit Download PDFInfo
- Publication number
- CN108949997A CN108949997A CN201810974373.7A CN201810974373A CN108949997A CN 108949997 A CN108949997 A CN 108949997A CN 201810974373 A CN201810974373 A CN 201810974373A CN 108949997 A CN108949997 A CN 108949997A
- Authority
- CN
- China
- Prior art keywords
- detection
- excretion body
- albumen
- lung cancer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Abstract
The invention discloses a kind of lung cancer detection marker and diagnostic kits.Excretion body CD171 albumen is preparing the application in pulmonary cancer diagnosis kit as detection target spot.The reagent of detection excretion body CD171 expressing quantity is preparing the application in pulmonary cancer diagnosis kit.The real-time fluorescence PCR detection reagent of detection excretion body CD171 protein mRNA expression amount preferably includes the qPCR primer of detection excretion body CD171 albumen, and upstream primer sequence is as shown in SEQ ID NO.1, and downstream primer sequence is as shown in SEQ ID NO.2.The invention discloses a kind of excretion body CD171 albumen can be used for diagnosing whether patient suffers from lung cancer by detecting the protein expression level of CD171.It was proved that CD171 albumen can effectively distinguish lung cancer and Healthy People.Therefore, the present invention provides new detection target spot for the early diagnosis detection of lung cancer.
Description
Technical field
The invention belongs to field of biological detection, it is related to a kind of lung cancer detection marker and diagnostic kit.
Background technique
Lung cancer (lung cancer) is the malignant tumour of incidence and case fatality rate first in current world wide, nearly 50 years
Come, many country's report lung cancer morbidity rates and the death rate obviously increase, wherein the lung cancer morbidity rate and death of male and female
Rate is ranked the first respectively and second in all malignant tumours.Lung cancer have become seriously threaten human health chest it is common
Malignant tumour.
Currently, the treatment means of preferred lung cancer are surgical operations, even if however implementing the excision of radical result
Operation, has some patientss still cannot reach higher survival rate.About 75% patients with lung cancer has belonged to advanced stage in diagnosis at present,
5 years survival rates are into about 15% or so.It is that current diagnosis lung cancer compares using bronchoscope, vertical diaphragm mirror or thoracocentesis biopsy
Reliable method, but these operations are not suitable for being used to the common inspection and continuous monitoring to disease.Therefore controlling for lung cancer is improved
Therapeutic effect and survival rate, unique measure be early diagnosed, early treatment.Early stage screening can make the drop by stages of pulmonary cancer diagnosis
Low, Resection Rate improves, and median survival interval extends, and survival rate improves within 5 years.So exploring the mark of new early detection lung cancer
Object carries out lung cancer early diagnosis, is very necessary.
Excretion body (exosome) is the small vesica of various kinds of cell active secretion, and diameter 40-100nm has lipid double
Film structure.Excretion body contains the Multiple components such as protein, lipid, nucleic acid, plays and focuses in the entire physiology course of cell
It acts on, excretion body enters body fluid after being discharged by cell, can be used as reliable tumor marker.The study found that excretion body can
To promote the formation of lung cancer microenvironment, to increase invasion and the transfer ability of tumour cell, participate in the generation for promoting lung cancer and
Development.
The diagnostic mode of detection lung cancer has chest X-ray, chest CT, Drug eluting stent etc. at present, but most of
All it is invasive operation, and is easy to be influenced by the size of tumor tissues or own situation of patient etc..And excretion body is used
Be in the advantage of lesion detection: operation is noninvasive, and can be in a variety of body fluid such as blood, sweat, urine, hydrothorax, ascites
Detection obtains.
Summary of the invention
The purpose of the present invention is being directed to the above-mentioned deficiency of the prior art, a kind of answering for new lung cancer biomarker is provided
With.
It is a further object of the present invention to provide the detection reagents of the lung cancer biomarker.
It is yet another object of the invention to provide pulmonary cancer diagnosis kits.
The purpose of the present invention can be achieved through the following technical solutions:
Excretion body CD171 albumen is preparing the application in pulmonary cancer diagnosis kit as detection target spot.
The reagent of detection excretion body CD171 expressing quantity is preparing the application in pulmonary cancer diagnosis kit.
The reagent of the detection excretion body CD171 expressing quantity preferably includes: detection excretion body CD171 protein mRNA
The real-time fluorescence PCR detection reagent of expression quantity；Or directly detect the western blot inspection of excretion body CD171 expressing quantity
Test agent.
The real-time fluorescence PCR detection reagent of the detection excretion body CD171 protein mRNA expression amount preferably includes to detect
The qPCR primer of excretion body CD171 albumen, upstream primer sequence is as shown in SEQ ID NO.1, downstream primer sequence such as SEQ ID
Shown in NO.2.
It is a kind of for detecting the qPCR primer of excretion body CD171 albumen, upstream primer sequence as shown in SEQ ID NO.1,
Downstream primer sequence is as shown in SEQ ID NO.2.
A kind of pulmonary cancer diagnosis kit, the real-time fluorescence PCR detection comprising detecting excretion body CD171 protein mRNA expression amount
Reagent.
The kit preferably includes the qPCR primer for detecting excretion body CD171 protein coding gene, in detection
Join the qPCR primer and the common reagent of other real-time fluorescence PCRs of β-Actin gene.
The qPCR primer upstream primer sequence of the detection excretion body CD171 protein coding gene is preferably such as SEQ ID
Shown in NO.1, downstream primer sequence is preferably as shown in SEQ ID NO.2.
The utility model has the advantages that
The invention discloses a kind of excretion body CD171 albumen can be used for examining by detecting the protein expression level of CD171
Whether disconnected patient suffers from lung cancer.It was proved that CD171 albumen can effectively distinguish lung cancer and Healthy People.By detecting blood
The expression of excretion body CD171 albumen can be used to the auxiliary diagnosis of patients with lung cancer in liquid, take diagnosis and treatment scheme to mention for clinician
For certain support.
Excretion body CD171 albumen is a kind of novel lesion detection marker, compared with traditional marker, CD171 egg
White Micro-operation is easy to detect, relatively stable, improves the sensibility and specificity of lung cancer detection.
Detailed description of the invention
Fig. 1 shows the expression by real-time fluorescence PCR detection excretion body CD171.
Fig. 2 shows sensibility and the spy that Healthy People group and patients with lung cancer group are distinguished using ROC curve analysis excretion body CD171
It is anisotropic.
Specific embodiment
The expression of 1 real-time fluorescence PCR detection CD171 albumen of embodiment
1, TRIzol method extracts total serum IgE and total protein
Blood sample extracts total serum IgE using TRIzol method, after RNA is extracted, 1 μ L is taken to be examined with 1% agarose gel electrophoresis
It surveys, and with Nanodrop2000 (Thermo Scientific) detectable concentration, and assesses RNA mass, 260/280 ratio is existed
RNA between 1.8-2.1 according toThe reversion of RT reagent Kit (TaKaRa) reverse transcription reagent box specification
Record becomes cDNA, and the cDNA of synthesis is saved backup under the conditions of -20 DEG C.
2, the design of primer
The gene order that CD171 and internal reference β-Actin are learnt according to Genbank inquiry, is set using software Primer 5.0
Count amplimer.
3, the expression of real-time fluorescence quantitative PCR detection CD171
(1) it reaction system: see the table below
(2) it reaction condition: see the table below
(4) statistical analysis
According to obtained Ct value, pass through 2-△△CtMethod calculate CD171 using β-Actin as relative expression's water of internal reference
Flat numerical value.
(5) result
The Ct value obtained according to real-time fluorescence quantitative PCR result, passes through 2-△△CtMethod carries out calculated result (Fig. 1) and health
Individual is compared, and CD171 expression quantity in patients with lung cancer is higher, has statistical significance.
The sensibility and specificity of the analysis excretion body CD171 albumen of embodiment 2
ROC curve analysis shows that, CD171 is distinguishing Healthy People group and when patients with lung cancer group, AUC value 0.8574,
Sensibility when best cut point is 71%, and specificity is 66% (Fig. 2), and excretion body CD171 is as potential lung as the result is shown
Cancer, which detects marker, has preferable sensitivity and specificity.
Sequence table
<110>Nanjing Qiu Zhen Gene Tech. Company Limited
<120>a kind of lung cancer detection marker and diagnostic kit
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
tacgagatcc acttgtttaa 20
<210> 2
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
actcacaaag ccgatgaac 19
<210> 3
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
cacccgcgat acaaccttc 19
<210> 4
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
ccatacccac catcacacc 19
Claims (8)
1. excretion body CD171 albumen is preparing the application in pulmonary cancer diagnosis kit as detection target spot.
2. the reagent of detection excretion body CD171 expressing quantity is preparing the application in pulmonary cancer diagnosis kit.
3. application according to claim 2, it is characterised in that the reagent of the detection excretion body CD171 expressing quantity
It include: the real-time fluorescence PCR detection reagent for detecting excretion body CD171 protein mRNA expression amount；Or directly detect excretion body
The western blot detection reagent of CD171 expressing quantity.
4. application according to claim 2, it is characterised in that the detection excretion body CD171 protein mRNA expression amount
Real-time fluorescence PCR detection reagent includes the qPCR primer for detecting excretion body CD171 albumen, upstream primer sequence such as SEQ ID
Shown in NO.1, downstream primer sequence is as shown in SEQ ID NO.2.
5. a kind of for detecting the qPCR primer of excretion body CD171 albumen, it is characterised in that upstream primer sequence such as SEQ ID
Shown in NO.1, downstream primer sequence is as shown in SEQ ID NO.2.
6. a kind of pulmonary cancer diagnosis kit, it is characterised in that include the real-time glimmering of detection excretion body CD171 protein mRNA expression amount
Light PCR detection reagent.
7. pulmonary cancer diagnosis kit according to claim 6, it is characterised in that the kit includes outer for detecting
It secretes the qPCR primer of body CD171 protein coding gene, detects the qPCR primer of internal reference β-Actin gene and other are glimmering in real time
The common reagent of light PCR.
8. pulmonary cancer diagnosis kit according to claim 6, it is characterised in that the detection excretion body CD171 albumen is compiled
The qPCR primer upstream primer sequence of code gene is as shown in SEQ ID NO.1, and downstream primer sequence is as shown in SEQ ID NO.2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810974373.7A CN108949997A (en) | 2018-08-24 | 2018-08-24 | A kind of lung cancer detection marker and diagnostic kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810974373.7A CN108949997A (en) | 2018-08-24 | 2018-08-24 | A kind of lung cancer detection marker and diagnostic kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108949997A true CN108949997A (en) | 2018-12-07 |
Family
ID=64474097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810974373.7A Pending CN108949997A (en) | 2018-08-24 | 2018-08-24 | A kind of lung cancer detection marker and diagnostic kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108949997A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110343750A (en) * | 2019-06-06 | 2019-10-18 | 宽盈医疗科技(上海)有限公司 | For detecting reference gene and its application of excretion body amplifying nucleic acid expression |
| CN112143814A (en) * | 2020-11-04 | 2020-12-29 | 上海思路迪生物医学科技有限公司 | Exosome ecDNA biomarker detection reagent for early diagnosis of lung cancer and application thereof |
| CN112415206A (en) * | 2020-10-23 | 2021-02-26 | 上海良润生物医药科技有限公司 | Application of CD171 protein in exosome as tumor metastasis diagnosis marker |
| CN112433054A (en) * | 2020-11-20 | 2021-03-02 | 四川大学华西医院 | Application of C9 protein detection reagent in preparation of lung cancer screening kit |
| CN113621708A (en) * | 2020-03-30 | 2021-11-09 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN114150066A (en) * | 2020-03-30 | 2022-03-08 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009137921A1 (en) * | 2008-05-14 | 2009-11-19 | University Health Network | Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy |
| CN107108741A (en) * | 2014-09-30 | 2017-08-29 | 德国公共权益癌症研究中心基金会 | With L1CAM（CD171）With reference to binding molecule, particularly antibody |
-
2018
- 2018-08-24 CN CN201810974373.7A patent/CN108949997A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009137921A1 (en) * | 2008-05-14 | 2009-11-19 | University Health Network | Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy |
| CN107108741A (en) * | 2014-09-30 | 2017-08-29 | 德国公共权益癌症研究中心基金会 | With L1CAM（CD171）With reference to binding molecule, particularly antibody |
Non-Patent Citations (1)
| Title |
|---|
| BIRGITTE SANDFELD-PAULSEN ET AL: "Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer", 《JOURNAL OF THORACIC ONCOLOGY》 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110343750A (en) * | 2019-06-06 | 2019-10-18 | 宽盈医疗科技(上海)有限公司 | For detecting reference gene and its application of excretion body amplifying nucleic acid expression |
| CN110343750B (en) * | 2019-06-06 | 2023-03-31 | 宽盈医疗科技(上海)有限公司 | Reference gene for detecting nucleic acid expression level in exosome and application thereof |
| CN114277144A (en) * | 2020-03-30 | 2022-04-05 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN114317745A (en) * | 2020-03-30 | 2022-04-12 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN113621708A (en) * | 2020-03-30 | 2021-11-09 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN114150066A (en) * | 2020-03-30 | 2022-03-08 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN114277145A (en) * | 2020-03-30 | 2022-04-05 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN114277138A (en) * | 2020-03-30 | 2022-04-05 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN114277138B (en) * | 2020-03-30 | 2022-06-24 | 中国医学科学院肿瘤医院 | Application of exosomes ARPC5, MBOAT2 and the like in lung cancer diagnosis |
| CN114277145B (en) * | 2020-03-30 | 2022-06-14 | 中国医学科学院肿瘤医院 | Application of exosomes ARPC5, FHL1 and the like in lung cancer diagnosis |
| CN114317746A (en) * | 2020-03-30 | 2022-04-12 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN114317745B (en) * | 2020-03-30 | 2022-06-07 | 中国医学科学院肿瘤医院 | Application of exosomes ARPC5, ERI3 and the like in lung cancer diagnosis |
| CN112415206A (en) * | 2020-10-23 | 2021-02-26 | 上海良润生物医药科技有限公司 | Application of CD171 protein in exosome as tumor metastasis diagnosis marker |
| CN112415206B (en) * | 2020-10-23 | 2023-08-18 | 上海良润生物医药科技有限公司 | Application of CD171 protein in exosome as tumor metastasis diagnosis marker |
| CN112143814A (en) * | 2020-11-04 | 2020-12-29 | 上海思路迪生物医学科技有限公司 | Exosome ecDNA biomarker detection reagent for early diagnosis of lung cancer and application thereof |
| CN112433054A (en) * | 2020-11-20 | 2021-03-02 | 四川大学华西医院 | Application of C9 protein detection reagent in preparation of lung cancer screening kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108949997A (en) | A kind of lung cancer detection marker and diagnostic kit | |
| CN105603101B (en) | Detect application of the system of 8 miRNA expression quantity in diagnosis or auxiliary diagnosis of hepatoma product is prepared | |
| CN101990577A (en) | Identification of novel pathways for drug development for lung disease | |
| CN108624695B (en) | One kind circulation miRNA marker relevant to thyroid papillary carcinoma auxiliary diagnosis and its application | |
| CN108728535A (en) | Applications of the hsa_circ_0049154 as prostate cancer molecular target in preparing drug and kit | |
| CN105483218A (en) | Seminal plasma piRNA markers or their combination for detecting and/or predicting male reproductive dysfunction and application thereof | |
| CN111172279A (en) | Model for diagnosing lung cancer by combined detection of peripheral blood methylation gene and IDH1 | |
| CN108624688A (en) | Applications of the hsa_circ_0012755 as prostate cancer molecular target in preparing drug and kit | |
| CN105154447B (en) | Applications of the AC016745.3 as prostate cancer molecular target and its in diagnostic kit | |
| CN110484624A (en) | A kind of gastric cancer biomarker and its detection method and application based on peripheral blood | |
| CN104711341A (en) | Application of DLK1 gene in preparation of gastrointestinal stromal tumor diagnostic reagent | |
| CN109609634A (en) | One kind circulation miRNA marker relevant to carcinoma of endometrium auxiliary diagnosis and its application | |
| CN107167604B (en) | FLOT1 is as the application in oophoroma biomarker | |
| CN106987633A (en) | A kind of primer and kit for detecting colorectal cancer serum secretion type lncRNAs | |
| CN104611430A (en) | Detection method and primers for TMPRSS2-ERG gene in human urine | |
| KR102211972B1 (en) | Method for early diagnosis of breast cancer and monitoring after treatment using liquid biopsy multi-cancer gene biomarkers | |
| WO2023050642A1 (en) | Application of alpha-fetoprotein or carcinoembryonic antigen combined with gene marker in tumor diagnosis | |
| CN104046685A (en) | Epigenetic biomarker adamts9 for diagnosis and prognosis of gastric cancer | |
| CN109593849A (en) | One group of blood plasma LncRNA marker relevant to colorectal cancer and its application | |
| CN109563548A (en) | For identifying the in-vitro method of cancer of pancreas or pancreatic intraductal papillary mucinous tumor | |
| CN103205423A (en) | Prostate cancer biomarker miR-126-5P, diagnostic kit and application | |
| CN112210603A (en) | Application of combined gene in esophageal squamous carcinoma | |
| CN106367477A (en) | Serum miRNA marker related to auxiliary diagnosis of colorectal cancer, and application thereof | |
| CN107723365B (en) | One kind blood plasma miRNA marker relevant to lung squamous cancer auxiliary diagnosis and its application | |
| CN110004227A (en) | A kind of biomarker of nasopharyngeal carcinoma diagnosis and/or prognosis evaluation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181207 |
|
| WD01 | Invention patent application deemed withdrawn after publication |